Sophie Heinzen
YOU?
Author Swipe
View article: Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024: Non-Targeted therapy in Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Thymic Epithelial Tumors
Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024: Non-Targeted therapy in Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Thymic Epithelial Tumors Open
The European Society for Medical Oncology (ESMO) Congress 2024 presented pivotal new data across various trials that continue to explore the nuances of immunotherapy (ICI) in non-small-cell lung cancer (NSCLC) and small cell lung cancer (S…
View article: Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis
Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis Open
Addition of single-agent CPI to cCRT is manageable in selected patients with stage III NSCLC. Efficacy outcomes appear to be in line with previous data of cCRT followed by CPI maintenance.
View article: Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024: Targeted Therapies in Non-Small Cell Lung Cancer
Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024: Targeted Therapies in Non-Small Cell Lung Cancer Open
View article: Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR Inhibition
Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR Inhibition Open
In this real-world study, EGFRi/METi showed clinical benefit over METi and SoC. Future studies should focus on the differential impact of the type of MET CNG with a focus on true MET amplification as predictor of response.
View article: Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancer
Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancer Open
Introduction Small cell lung cancer (SCLC) is a rapidly growing malignancy with early distant metastases. Up to 70% will develop brain metastases, and the poor prognosis of these patients has not changed considerably. The potential of chec…